Total Cost of Insulin Workgroup

July 8, 2022
10:00 am – 1:00 pm
Meeting Link

WORKGROUP MEMBERS

☐ Donna Sullivan – Chief Pharmacy Officer, HCA
☐ Mary Fliss – Deputy, Clinical Strategy and Operations, HCA
☐ Barbara Hewitt Jones – Office of the Insurance Commissioner
☐ William Hayes – Dept of Corrections
☐ Lumi Nodit – Office of Attorney General
☐ Dan Gossett – School Employees Benefit Board
☐ Kat Kahachatourian – Pharmacy Quality Assurance Commission
☐ Chris Bandoli – Assoc. of Washington Health Plans
☐ Kevin Wren – Washington Insulin For All

☐ Jenny Arnold – Washington Pharmacy Association
☐ Leah Lindahl – Healthcare Distribution Alliance
☐ LuGina Mendez-Harper – PCMA
☐ Lori Evans – Public member
☐ Laura Keller – Public member
☐ Amber Markland – Public member
☐ Jennifer Perkins – Public member
☐ Mike Bonetto – Center for Evidence-based Policy

☐ Nonye Connor – Project Manager, HCA
☐ Leta Evaskus – NW Prescription Drug Consortium Operations Manager
☐ Ryan Pistoresi – Assistant Chief Pharmacy Officer, HCA
☐ Hayley De Carolis – Center for Evidence-based Policy
☐ Brittany Lazur – Center for Evidence-based Policy
☐ Mandi Mizuta – Center for Evidence-based Policy
☐ Susan Stuard – Center for Evidence-based Policy
☐ Dan Vizzini – Center for Evidence-based Policy

Main Outcome:
- Review 2022 Legislation (SB 1728) and Scope of Work
- Overview of HCA cost analysis work on Senate Bill 5203 (2021)
  - Directs HCA to establish partnerships to produce, distribute or purchase generic prescription drugs and insulin.
- Review and discuss Workgroup survey results
- Workgroup discussion and feedback

<table>
<thead>
<tr>
<th>No</th>
<th>Agenda Items</th>
<th>Time</th>
<th>Lead</th>
<th>Summary Meeting Notes</th>
</tr>
</thead>
</table>
| 1. | Welcome and Opening Business  
  - Introductions and icebreaker  
  - Meeting overview  
  - Announcement about changes to Open Public Meeting Act | 30 | Mary Fliss – Deputy, Clinical Strategy and Operations, HCA |
<p>| 2. | Review 2022 Legislation (SB 1728) and Scope of Work | 20 | Brittany Lazur – Center for Evidence-based Policy |
| 3. | Overview of HCA Cost Analysis from SB 5203 | 50 | Dan Vizzini – Center for Evidence-based Policy |
| 4. | Break | 10 | |
| 5. | Overview and Discussion of Workgroup Survey Results | 60 | Mike Bonetto – Center for Evidence-based Policy |
| 6. | Next Steps | 10 | Mary Fliss – Deputy, Clinical Strategy and Operations, HCA |</p>
<table>
<thead>
<tr>
<th>#</th>
<th>Action Item</th>
<th>Assigned To</th>
<th>Date Assigned</th>
<th>Date Due</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>